Vanguard Global Advisers’s Ovid Therapeutics OVID Stock Holding History
Bought
Maintained
Sold
Other funds holding OVID
Vanguard Global Advisers's OVID Position: Q3 2026 in Review
Vanguard Global Advisers increased its Ovid Therapeutics (OVID) stake by 102% in Q3 2026, buying an estimated $189K and bringing the position to 142,707 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #2251.
Vanguard Global Advisers first reported a position in OVID in Q1 2026 and has held it in 3 quarters since. 127 funds tracked by Wall St. Rank hold OVID as of Q3 2026.
- Vanguard Global Advisers held 142,707 shares of Ovid Therapeutics worth $355K as of Q3 2026.
- Vanguard Global Advisers bought 72,180 Ovid Therapeutics shares in Q3 2026, an estimated $189K.
- Ovid Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2251 holding.
- Vanguard Global Advisers first reported a position in Ovid Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 127 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.